The U.K.'s National Institute for Health and Care Excellence (NICE) recommended that Astrazeneca plc's Imfinzi (durvalumab) be available through the Cancer Drugs Fund for people with locally advanced unresectable non-small-cell lung cancer who have already had platinum-based chemoradiation.